Monthly usage reaches hundreds of cases at adopting hospitals, highlighting the potential for PPU-based recurring revenue
Intracranial hemorrhage AI reference expected to expand into aortic dissection and pulmonary embolism
As emergency department workforce shortages and the growing burden of critically ill patients become structural challenges for healthcare systems, emergency imaging AI is drawing increasing attention as it moves toward broader institutional adoption. In time-critical conditions such as intracranial hemorrhage, where delays in diagnosis and treatment can directly affect patient outcomes, AI is playing an increasingly important role by rapidly identifying patients who require immediate review after CT imaging and alerting clinicians.
Against this backdrop, Coreline Soft’s AI-assisted intracranial hemorrhage detection solution, AVIEW NeuroCAD, is moving beyond initial deployment to achieve repeated use within real-world emergency care workflows. The company is currently conducting two clinical validation projects at Yonsei Severance Hospital and Gangnam Severance Hospital, aimed at generating evidence on the clinical effectiveness and economic value of emergency AI while supporting future health technology assessments for reimbursement.
The significance of these projects extends beyond validating algorithm performance. The primary objective is to determine whether AI can reduce interpretation delays, improve clinical decision-making, and enhance operational efficiency in real emergency care settings. Yonsei Severance Hospital is developing an economic evaluation model for AI-assisted intracranial hemorrhage detection software, while Gangnam Severance Hospital is conducting a real-world clinical use evaluation.
These initiatives reflect changing standards for evaluating medical AI as it enters mainstream healthcare. Whereas performance was once measured primarily by diagnostic accuracy, greater emphasis is now being placed on how consistently AI is used in daily clinical practice, how effectively it improves hospital workflows, and whether it can generate the evidence required to support reimbursement and expanded non-reimbursed clinical use.
Following its designation as an Innovative Medical Device, AVIEW NeuroCAD has steadily expanded its real-world use under Korea's non-reimbursed clinical pathway. According to the company, cumulative usage exceeded 50,000 cases as of April, up from 30,000 cases in October last year—an increase of 20,000 cases in approximately six months. The growth suggests more than an increase in customer adoption; it indicates that AI is becoming a routine component of emergency imaging workflows, with clinicians repeatedly calling upon the system during daily practice.
Hospitals using AVIEW NeuroCAD are also reporting substantially higher utilization. Several institutions now use the solution for hundreds of emergency cases each month, suggesting that emergency AI is evolving beyond pilot deployments and early validation into an operational support infrastructure embedded within emergency department workflows.
A leading example is Pohang Semyung Christianity Hospital, a regional cardiovascular and cerebrovascular emergency center serving North Gyeongsang Province. The hospital uses AVIEW NeuroCAD to support rapid collaboration between its emergency department and radiology team. The solution is now used in hundreds of cases each month, demonstrating how AI can move beyond image interpretation assistance to help prioritize emergency patients and accelerate diagnosis as part of hospital operational innovation.
A hospital official said, "In the emergency department, quickly identifying patients with time-critical conditions such as intracranial hemorrhage is essential. AVIEW NeuroCAD immediately flags suspected findings during CT analysis, enabling clinicians to respond proactively."
The official added, "Emergency medicine requires countless decisions to be made within a very short period of time. NeuroCAD serves as a reliable clinical assistant that helps physicians establish treatment strategies safely and quickly. Because reducing diagnosis time by even a few minutes can change patient outcomes, the solution provides practical value by improving the early detection of cerebrovascular emergencies and supporting faster clinical response."
One of the market's key areas of interest is whether this growing level of real-world utilization can translate into a Pay-Per-Use (PPU) revenue model. Rather than generating revenue only through one-time installation, medical AI can increasingly create recurring revenue as usage accumulates through routine imaging and interpretation.
Coreline Soft believes its initial installation revenue can evolve into recurring PPU revenue linked directly to actual hospital utilization. Emergency AI is particularly well suited to this model because usage frequency is high and naturally increases as the solution becomes integrated into routine clinical workflows. Beyond intracranial hemorrhage, demand for AI-assisted triage, alerts, and interpretation support is also expected to expand into other time-sensitive emergency conditions, including aortic dissection (Aorta) and pulmonary embolism (PE).
This trend is also becoming visible in the company's financial performance. In the first quarter, Coreline Soft reported a 319.7% year-over-year increase in PPU revenue, indicating that its business model is shifting from one-time software sales toward SaaS-style, usage-based recurring revenue. The continued growth in NeuroCAD utilization suggests that this transition is beginning to take hold within Korea's emergency care environment.
AVIEW NeuroCAD's growing clinical reference base could also support expansion across Coreline Soft's broader emergency AI portfolio. In addition to intracranial hemorrhage, the company offers AI solutions for emergency conditions, including aortic dissection and pulmonary embolism. Rather than deploying separate AI applications for each disease, hospitals are increasingly expected to seek integrated CT-based emergency workflow solutions capable of identifying multiple life-threatening conditions and notifying clinicians through a unified platform.
As AVIEW NeuroCAD becomes established within hospital workflows, opportunities are expected to grow for cross-deployment of the company's Aorta and PE solutions within the same emergency care pathway. Such expansion could increase revenue per hospital, strengthen product retention, and accelerate the development of an emergency AI platform supported by recurring revenue across multiple products.
Standards for evaluating medical AI continue to evolve. The key question is no longer how widely AI has been installed, but how consistently and repeatedly it is used in routine clinical practice. The NeuroCAD case illustrates how emergency AI may move beyond technical validation toward a usage-based commercialization model supported by real-world clinical adoption.
